Drugs / FTC/TDF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01106586 Comparator | Apr 2010 → Sep 2011 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FTC/TDF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01106586 ↗ |
| Action | Inhibit | “standard of care nucleoside reverse transcriptase inhibitor (NRTI) backbone FTC/TDF” NCT01106586 ↗ |
| Modality | Other / unclassified | “standard of care nucleoside reverse transcriptase inhibitor (NRTI) backbone FTC/TDF” NCT01106586 ↗ |
| Route | Oral | “FTC/TDF 200/300 mg tablet administered orally once daily” NCT01106586 ↗ |